CryABR120G Knock-in Mutation Alone Insufficient to Induce Overt Cardiomyopathy in Mice
Background
Autosomal dominant cardiomyopathy in humans is linked to a missense mutation (R120G) in alpha B-crystallin (CryAB), a crucial small heat-shock protein highly expressed in cardiac tissue. CryAB functions as a molecular chaperone, preventing protein aggregation, especially under stress. The R120G mutation leads to extensive protein aggregation in cardiomyocytes, but the precise pathogenic mechanisms remain unclear. Appropriate in vivo models are essential to investigate disease pathogenesis and evaluate potential therapeutic strategies for this debilitating condition.
Study Design
Researchers characterized a homozygous CryABR120G knock-in (KI) mouse model to assess the mutation's impact on cardiac function. Mice were observed up to 12 months of age. The study evaluated cardiac structure and function, cardiac and proteotoxic stress markers, and protein quality control pathways. Mitochondrial respiration was also assessed in young and 12-month-old CryABR120G KI mice. The primary endpoint was the development of overt structural or functional cardiomyopathy, with wild-type littermates serving as the control arm.
Results
Despite the presence of insoluble protein aggregates, homozygous CryABR120G KI mice exhibited no overt changes in cardiac structure and function through 12 months of age. Minimal changes were observed in cardiac and proteotoxic stress markers, with one notable exception: an increased atrial natriuretic peptide expression at 12 months. Protein quality control pathways remained largely unchanged throughout the study period. While mitochondrial respiration was normal in young CryABR120G KI mice, it was significantly reduced at 12 months of age. These findings collectively indicate that the CryABR120G KI model, within the examined age range, does not fully reproduce the severe cardiomyopathic phenotype seen in human patients. This suggests that additional factors or genetic modifiers might be necessary for the full manifestation of the disease in this model.
Homozygous
CryABR120GKI mice did not develop overt structural or functional cardiomyopathy through 12 months of age, despite insoluble protein aggregates.
Key Findings
CryABR120GKI mice showed no overt cardiac structural or functional changes up to 12 months of age.- Minimal changes in cardiac and proteotoxic stress markers, except increased
atrial natriuretic peptideat 12 months. - Mitochondrial respiration was normal in young mice but reduced at 12 months of age.
- Insoluble protein aggregates were present in
CryABR120GKI mice, but without overt cardiomyopathy.
Why It Matters
This study highlights that the CryABR120G mutation alone may not be sufficient to induce overt cardiomyopathy in mice, suggesting a more complex etiology for the human disease. For researchers and biohackers, this implies that therapeutic strategies solely targeting the CryABR120G mutation might need to consider other contributing factors or genetic modifiers. The model's failure to fully recapitulate the human phenotype means that future preclinical studies for CryABR120G-associated cardiomyopathy may require additional stressors, genetic backgrounds, or longer observation periods to develop a more clinically relevant model. This work underscores the challenges in translating genetic findings from human patients to animal models for complex cardiac conditions.
cryabr120g
cardiomyopathy
mouse-model
protein-aggregation
mitochondrial-dysfunction
cardiac-function